USD
$0.00
(0.00%
)At Close (As of Oct 13, 2025)
$252.00B
Market Cap
18.93
P/E Ratio
6.87
EPS
$133.55
52 Week High
$92.72
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $39B |
Total Revenue | $52B |
Cost Of Revenue | $13B |
Costof Goods And Services Sold | $13B |
Operating Income | $15B |
Selling General And Administrative | $13B |
Research And Development | $10B |
Operating Expenses | $24B |
Investment Income Net | - |
Net Interest Income | -$608M |
Interest Income | $568M |
Interest Expense | $1B |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $6.1B |
Income Before Tax | $14B |
Income Tax Expense | $1.7B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $12B |
Comprehensive Income Net Of Tax | - |
Ebit | $15B |
Ebitda | $21B |
Net Income | $12B |
Field | Value (USD) |
---|---|
Total Assets | $102B |
Total Current Assets | $30B |
Cash And Cash Equivalents At Carrying Value | $11B |
Cash And Short Term Investments | $11B |
Inventory | $5.7B |
Current Net Receivables | $8.2B |
Total Non Current Assets | $73B |
Property Plant Equipment | $11B |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $27B |
Intangible Assets Excluding Goodwill | $27B |
Goodwill | $25B |
Investments | - |
Long Term Investments | $1.1B |
Short Term Investments | $1.9B |
Other Current Assets | $2.4B |
Other Non Current Assets | - |
Total Liabilities | $58B |
Total Current Liabilities | $29B |
Current Accounts Payable | $4.6B |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $8.3B |
Total Non Current Liabilities | $29B |
Capital Lease Obligations | $1.8B |
Long Term Debt | $21B |
Current Long Term Debt | $8.1B |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $31B |
Other Current Liabilities | $13B |
Other Non Current Liabilities | $1B |
Total Shareholder Equity | $44B |
Treasury Stock | - |
Retained Earnings | $47B |
Common Stock | $793M |
Common Stock Shares Outstanding | $2B |
Field | Value (USD) |
---|---|
Operating Cashflow | $18B |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $6.1B |
Capital Expenditures | $3.8B |
Change In Receivables | - |
Change In Inventory | -$225M |
Profit Loss | - |
Cashflow From Investment | -$7.5B |
Cashflow From Financing | -$12B |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $7.6B |
Dividend Payout Common Stock | $7.6B |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$8.3B |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $12B |
Field | Value (USD) |
---|---|
Gross Profit | $39B |
Total Revenue | $52B |
Cost Of Revenue | $13B |
Costof Goods And Services Sold | $13B |
Operating Income | $15B |
Selling General And Administrative | $13B |
Research And Development | $10B |
Operating Expenses | $24B |
Investment Income Net | - |
Net Interest Income | -$608M |
Interest Income | $568M |
Interest Expense | $1B |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $6.1B |
Income Before Tax | $14B |
Income Tax Expense | $1.7B |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $12B |
Comprehensive Income Net Of Tax | - |
Ebit | $15B |
Ebitda | $21B |
Net Income | $12B |
Field | Value |
---|---|
Ex Dividend Date | 2025-03-12 |
Declaration Date | 2025-02-20 |
Record Date | 2025-03-12 |
Payment Date | 2025-04-25 |
Amount | 3.99399 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Novartis AG is a leading global healthcare company based in Basel, Switzerland, focused on the research, development, manufacturing, and marketing of innovative pharmaceuticals and medical devices. With a strong portfolio of patented medicines across various therapeutic areas, including oncology, cardiology, and immunology, Novartis is committed to improving patient outcomes through cutting-edge science and technology. The company's emphasis on research and development, coupled with strategic collaborations, positions it as a key player in the evolving healthcare landscape, making it an attractive investment option for institutional investors.